In our study, we showed that DLBCL patients alive after 12 months of follow-up, those with serum sCD163 levels above the median had a significantly worse overall survival than patients with serum sCD163 levels below the median (p = 0.03), as shown in Figure 1. The gene discussed is CD163; the disease is diffuse large B-cell lymphoma.